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Mesenchymal stromal cells (MSCs) are adult, multipotent cells of mesodermal origin
representing the progenitors of all stromal tissues. MSCs possess significant and
broad immunomodulatory functions affecting both adaptive and innate immune
responses once MSCs are primed by the inflammatory microenvironment. Recently,
the role of extracellular vesicles (EVs) in mediating the therapeutic effects of MSCs
has been recognized. Nevertheless, the molecular mechanisms responsible for
the immunomodulatory properties of MSC-derived EVs (MSC-EVs) are still poorly
characterized. Therefore, we carried out a molecular characterization of MSC-EV content
by high-throughput approaches. We analyzed miRNA and protein expression profile in
cellular and vesicular compartments both in normal and inflammatory conditions. We
found several proteins andmiRNAs involved in immunological processes, such asMOES,
LG3BP, PTX3, and S10A6 proteins, miR-155-5p, and miR-497-5p. Different in silico
approaches were also performed to correlate miRNA and protein expression profile
and then to evaluate the putative molecules or pathways involved in immunoregulatory
properties mediated by MSC-EVs. PI3K-AKT signaling pathway and the regulation of
actin cytoskeleton were identified and functionally validated in vitro as key mediators of
MSC/B cell communication mediated by MSC-EVs. In conclusion, we identified different
molecules and pathways responsible for immunoregulatory properties mediated by
MSC-EVs, thus identifying novel therapeutic targets as safer and more useful alternatives
to cell or EV-based therapeutic approaches.
Keywords: extracellular vesicles, mesenchymal stromal cells, B cells, high-throughput analysis, PI3K-AKT
signaling pathway, actin cytoskeleton, miRNA-155-5p
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INTRODUCTION
Intercellular communication amongst neighboring cells usually
occurs either through cell-to-cell contact or exchange of
soluble factors. The latter mechanism rarely occurs through the
simple secretion of molecules in the intercellular space, which
would lead to their rapid inactivation especially if released at
tiny concentrations. A very effective, physiological intercellular
communication, even at low molecule concentrations, is
represented by the exchange of extracellular vesicles (EVs). EVs
consist of a membrane-like envelope, i.e., spherical phospholipid
bilayer surrounding various molecules, such as proteins, DNA,
different types of RNAs (mRNAs, miRNAs, and lncRNAs), lipids,
and active metabolites. EVs are shedding vesicles acting as
molecular shuttles, constantly released by the cells in a sort
of assembly chain process, which are characterized by different
size and molecular content according to their origin, biogenesis,
and cellular functional status (1–4). EVs include exosomes (50–
100 nm), microvesicles (100–1,000 nm), apoptotic bodies (1–
5µm), and some other membrane-bound particles. Exosomes
originate frommultivesicular body and contain common protein
families, such as chaperones (Hsp70 and Hsp90), cytoskeletal
proteins (actin, myosin and tubulin), ESCRT proteins (TSG-101
and Alix), proteins involved in transport and fusion (Rab11,
Rab7, Rab2, and Annexines) as well as tetraspanin proteins
(CD9, CD63, CD81, and CD82) (5–7). Microvesicles result
from plasmatic membrane gemmation and contain specific
cytoplasmatic proteins of the cells of origin, such as GTP-
binding protein, ADP-ribosylation factor 6 (ARF6), matrix
metalloproteinases (MMPs), glycoproteins (e.g., GPIb, GPIIb-
IIIa), integrins, receptors (e.g., EGFRvIII), and cytoskeletal
components (e.g., β-actin and α-actinin-4) (5, 6). In addition,
both exosomes and microvesicles contain a large number of
molecules, whose functions are still under investigation (8).
By contrast, apoptotic bodies are functionally different by the
other two kinds of EVs, as they result from the programmed
cell death mechanisms and contain DNA, histones, and cellular
debris derived from cell dismantlement; their formation is a
highly controlled mechanism preventing leakage of potentially
toxic, enzymatically active or immunogenic components of dying
cells, thereby preventing tissue destruction, inflammation, and
autoimmune reactions through cytoskeleton weakening and
activation of caspase enzymes. In addition, apoptotic bodies
act as a powerful signaling pathway for the microenvironment
surrounding dying cells (1–4).
The secretion of EVs is not restricted to mammalian
cells, but it has been also identified in lower eukaryotes and
prokaryotes, highlighting a high degree of conservation of
such communication system and, consequently, its relevance
in intercellular communication (9, 10). EVs influence various
biological process directly activating cell surface receptors
through protein and bioactive lipid ligands, and delivering
effectors including transcription factors, oncogenes, mRNAs,
and non-coding regulatory RNAs, such as miRNAs into target
cells (11–13).
EVs play a role also during the onset of immune responses.
EVs possess immunosuppressive effects on T cells and NK
cells and play a crucial role in the induction of regulatory T
and myeloid cells to further inhibit the immune response (14–
16). EVs in co-culture with peripheral blood mononuclear cells
(PBMCs) inhibit B cell proliferation and immunoglobulin release
(17). Placenta-derived exosomes, purified from the blood of
pregnant women, carry immunosuppressive molecules, such as
Fas-ligand, which induce tolerance toward the fetus (1–4). On the
other hand, EVs may also stimulate the immune system, with the
final effect depending onmany factors, such as effector and target
cells as well as the biological context in which this interaction
takes place (1, 4, 18).
Even the immune regulatory properties of stromal cells
can be influenced by EV release, as shown by a number of
data obtained with mesenchymal stromal cells (MSCs) derived
from bone marrow (BM) or other tissues (19, 20). MSCs are
adult, multipotent cells of mesodermal origin representing the
progenitors of all stromal tissues. In fact, although they were
first identified and isolated from BM, MSCs can be expanded
from virtually any tissue with a stromal architecture, including
adipose tissue, umbilical cord blood, skin, tendon, muscle, and
dental pulp (21–24). MSCs are characterized by the ability
to differentiate into mesodermal tissues, such as osteoblasts,
chondrocytes, and adipocytes, with therapeutic potential in
the field of regenerative medicine (25, 26). However, MSCs
possess also significant and broad immune modulatory functions
affecting both adaptive and innate immune responses once
MSCs are primed by the inflammatory microenvironment (27).
MSC-mediated immune regulation has been confirmed by both
preclinical and clinical studies based on systemic or local
MSC administration in a broad spectrum of inflammatory and
autoimmune diseases, such as Graft-vs.-Host Disease (GvHD)
(28), Crohn’s disease and enteropathies (29–31), as well as
in cardiovascular disease (32, 33), acute kidney injury (34),
colitis, sepsis (35), and other disorders (36). The beneficial
effect of MSCs was initially ascribed to their ability to home
within the inflammation sites, thus stimulating endogenous
repair of the injured tissue and modulating immune responses
(37–39); actually, only a negligible percentage of systemically
administered MSCs is capable of reaching the damaged tissues
(40, 41). Therefore, MSC biological activity–in terms of both
regeneration and immunomodulation–is supposed to reside in
their ability to act at paracrine level through the release of
bioactive factors, as observed with cardiomyocytes exposed to
hypoxia/reoxygenation (42), or through indirect mechanisms
involving phagocytes (43). Recently, the role of EVs in mediating
the paracrine effects of MSCs has been recognized both in
tissue repair and immunomodulation (19, 20). Nevertheless, the
molecular mechanisms responsible for the immunomodulatory
role ofMSC-derived EVs are still poorly characterized. Therefore,
in this study we carried out a high-throughput characterization
of miRNA and protein expression in MSCs at resting conditions
(control MSCs, cMSCs), inflammatory conditions (primed-
MSCs, pMSCs), and corresponding EVs (cEVs and pEVs,
respectively). We then functionally validated the modulated
molecules and we focused our analysis on those involved in
the crosstalk between MSCs and B cells for the following
reasons: (i) we and other groups have previously demonstrated
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that B cell activity is strongly modulated by EVs released by
MSCs (20, 44); (ii) the characterization of the EV-mediated
interactions between normal B cells and MSCs represents the
basis for studying the same crosstalk in inflammatory and
autoimmune diseases as well as in hematological malignancies
(45–47). The molecules and pathways here identified are
important for the immunoregulatory properties mediated by
MSC-EVs and may represent some novel potential therapeutic
targets as safer and more useful alternatives to cell or EV-
based therapeutic approaches for inflammatory, autoimmune
and proliferative disorders.
RESULTS
Size and Surface Marker Characterization
of MSC-Derived EVs
To characterize MSC-derived EVs, we first analyzed their
size using dynamic light scattering (DLS). We identified two
separate, equally represented populations of EVs derived from
resting MSCs (Figure 1A). The small-sized EVs, ranging from
30 to 100 nm (peak 40.43 ± 15.63 nm, percentage 46.6%),
corresponded to exosomes. The large-sized population of EVs,
ranging from 100 to 400 nm (peak 207.7 ± 53.95 nm, percentage
53.4%), corresponded to microvesicles. The percentage of
exosomes was significantly higher as compared to microvesicles
in EVs derived from primed MSCs (75.1 and 24.9%, respectively)
(Figure 2B). Furthermore, we re-analyzed the size of EVs after
freezing and thawing the samples. We observed the same
DLS profile, demonstrating that EVs maintained their integrity
(Figures 1C,D). To assess the surface marker profile of MSC-
derived EVs, we used amultiplex bead-based platform that allows
the detection of 37 surface epitopes. Both resting and primed-EVs
were positive for the well-established exosome markers CD63,
CD81, and CD9 (Figure 1E). In particular, CD63 intensity was
higher compared to CD81 and CD9 expression. As the cells
of origin, MSC-derived EVs were positive for CD29, CD44,
CD105, and negative for hematopoietic, epithelial, and cancer
stem cell markers (Figure 1F). Moreover, MSC-derived EVs
expressed SSEA-4 (Figure 1F), an early embryonic glycolipid
antigen identifying the adult MSC population derived from
BM (48). Furthermore, we found a significant expression of
CD146 (Figure 1F), a typical molecule characterizing a specific
subpopulation of MSCs with a higher therapeutic potential
(49). Western blot analysis confirmed the surface marker
profile of EVs, as far as the exosome marker CD63 and
the hMSC-associated markers CD44, CD105, and CD146 are
concerned (Figure 1G).
MSC-Derived EV Internalization by
Activated B Lymphocytes
To evaluate a possible role of MSC-derived EVs in modulating
B cell activity, we first assessed the potential of MSCs to
transfer membrane fragments and RNA molecules to activated
B lymphocytes. To this aim, activated B lymphocytes were
co-cultured with resting or primed MSCs labeled or not at
membrane (Vibrant DiI) and RNA (Syto RNA Select) level with
fluorescent probes. The transfer of MSC-derived membrane and
RNA was observed at different culture times by flow cytometry.
We detected a double-positive B cell population receiving
MSC-derived EVs containing RNA (Figures 2D,F). EVs derived
from both resting and primed MSCs were internalized by
activated B lymphocytes. Initial incorporation was observed
after 24 h of co-culture, followed by an increase until 72 h.
At each time points we observed a higher internalization of
cEVs compared to pEVs (Figure 2A). The same trend was
observed considering separately the internalization of MSC-
derived membranes and RNA molecules, with a more marked
effect on RNA transfer (Figures 2B,C). Considering that pMSCs
release a higher percentage of exosomes compared to cMSCs,
which represent smaller sized-EVs compared to microvesicles,
the difference observed in terms of EV internalization may
result from the difference in size of internalized particles. To
further confirm our hypothesis, we directly co-cultured activated
B cells with double-labeled resting or primed EVs and the same
experiments were carried out by flow cytometry. As expected,
after 24 h we observed a higher internalization of cEVs compared
to pEVs (Figures 2G,H). EV incorporation was also assessed by
fluorescence microscopy (Figure 2E). Overall, our data showed
that the uptake of MSC-derived EVs occurs at both resting and
primed conditions, thus highlighting a possible involvement of
EVs in modulating B cell activity.
Proteomic Profiling of MSCs and EVs
To identify proteins potentially involved in immunomodulatory
properties mediated by pEVs, MSCs treated or not with
inflammatory stimuli and corresponding EVs were analyzed
using shotgun MS. A complete list of the identified proteins
is shown in Table S1. As expected, the number of identified
proteins in the cells is higher compared to that identified in
the EV compartment. Nevertheless, the number of modulated
proteins is similar among the two compartments (Figure S1
and Table S2).
To assess the overall variation of the samples following
inflammatory stimuli, shotgun MS data were processed by
PCA. The score plot of the first two PCs calculated for EVs
(Figure 3A) and MSCs (Figure 3B) allows the clear separation of
the sample groups, thus indicating that the information about the
inflammatory stimuli is present in the protein profile of both EVs
and MSCs samples; nevertheless, in the case of EVs, two samples
(BM004 and D24) seem quite different as they are far from the
others located at the origin of the axes.
We analyzed differentially expressed proteins in pEVs and
pMSCs using both univariate and multivariate approaches. By
using the univariate analysis, we found 55 and 39 proteins
differentially expressed in pEVs and in pMSCs, respectively
(Table S3). Using the multivariate approach, based on Ranking-
PCA followed by PLS-DA, we found 181 and 363 proteins
differentially expressed in pEVs and in pMSCs, respectively,
considering 1 PC in Ranking-PCA and 1 LV in the final PLS-
DA models (for MSCs, only the first 200 proteins selected
by Ranking-PCA were included in the PLS-DA model).
Figures 3C,D report the score plots of the first 2 LVs for
EVs and MSCs, respectively. Selected proteins clearly separate
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FIGURE 1 | Size and surface marker characterization of MSC-derived EVs. Histograms represent hydrodynamic diameter distribution plots measured on EVs freshly
isolated from resting (A) and primed MSC (B) (cEVs exosomes peak 40.43 ± 15.63 nm, percentage 46.6%; cEVs microvesicles peak 207.7 ± 53.95 nm, percentage
53.4%; pEVs exosomes peak 51.17 ± 23.23 nm, percentage 75.1%; pEVs microvesicles peak 200.9 ± 63.57 nm, percentage 24.9%). (C) Hydrodynamic diameter
distribution of cEV stored at −80◦C (cEVs exosomes peak 51.08 ± 21.07 nm, percentage 59%; cEVs microvesicles peak 196.9 ± 65.34 nm, percentage 41%).
(D) Hydrodynamic diameter distribution of pEV stored at −80◦C (pEVs exosomes peak 55.91 ± 21.99 nm, percentage 83.6%; pEVs microvesicles peak 201.1 ±
76.45 nm, percentage 16.4%). Error bars represent mean ± SD obtained from at least five measurements of three independent samples. All experiments were
performed in PBS at 25◦C. (E) Background corrected median fluorescence intensity of CD9, CD63, CD81 markers and corresponding isotype controls on cEVs and
pEVs (n = 5). (F) Background corrected median fluorescence intensity of 34 surface epitopes on cEVs and pEVs (n = 5). (G) Immunoblot analysis of CD44, CD146,
CD105, and CD63 expression in cEVs and pEVs. This blot is representative of three independent experiments showing the same trends.
resting from primed samples (BM0004 and D24 EVs samples
are no more separated from the others as in PCA analysis).
The obtained models allowed the perfect classification of all
the replications of all the samples (NER% = 100%, accuracy =
100%), both in fitting and in cross-validation for both EVs and
MSCs. The list of candidate biomarkers identified by multivariate
analysis and the corresponding regression coefficients are
provided in Table S4. Variables with a positive coefficient
correspond to up-regulated proteins, while those characterized
by a negative coefficient correspond to down-regulated proteins.
The variables can be ordered according to a decreasing
discrimination ability on the basis of the decreasing absolute
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FIGURE 2 | Incorporation of MSC-EVs and RNA transfer in activated B lymphocytes. (A) Percentage of Vibrant DiI+ Syto RNA Select+ B cells co-cultured for 24, 48,
and 72 h with double stained resting or primed MSCs (n = 5) *p < 0.05. (B) Vybrant Dil Geometric Mean of Fluorescence Intensity (GMFI) of B cells co-cultured with
(Continued)
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FIGURE 2 | double stained resting or primed MSCs. (C) Syto RNA Select GMFI of B cells co-cultured with double stained resting or primed MSCs. (D) Representative
gating strategy on the final gated population. (E) MSC-EVs were double-stained for membrane in red (Vybrant Dil) and for RNA in green (Syto RNA Select). Labeled
EVs were incubated for 24 h on activated B lymphocytes. The four panels show (from the left to the right) B cells stained with DAPI (blue), the internalization of
membrane components of cEVs and pEVs (red), the distribution of Syto RNA Select carried by MSC-EVs inside B cells (green), and a merge between the three
previous panels (original magnification 400x). The images are representative for three independent experiments with similar results. (F) Representative FACS analysis
of Vibrant DiI+ Syto RNA Select+ B cells co-cultured with double stained (right) or not (left) resting or primed MSCs. (G) Percentage of Vibrant DiI+ Syto RNA Select+
B cells co-cultured for 24 h with double stained resting or primed MSC-EVs (n = 5) *p < 0.05. (H) Representative FACS analysis of Vibrant DiI+ Syto RNA Select+ B
cells co-cultured with double stained (right) or not (left) resting or primed MSC-EVs.
FIGURE 3 | Overall variation of differentially expresses proteins in MSCs and EVs following inflammatory priming and PLS-DA. Score plot of the first two PCs
calculated after the application of PCA to EVs (A) and MSCs (B). Score plot of the first two LVs calculated after the application of PLS-DA to the 181 proteins selected
by Ranking-PCA on the EVs dataset (C) and on the first 200 proteins selected by Ranking-PCA on the MSCs dataset (D). Score plot of the first two LVs calculated
after the application of PLS-DA to the 55 proteins selected by univariate statistics on the EVs dataset (E) and on the 39 proteins selected by univariate statistics on the
MSCs dataset (F).
value of the regression coefficient. The multivariate models
were compared to PLS-DA models built including the markers
identified as statistically significant by classical univariate
statistics (Figures 3E,F) and provided the same classification
performances (100% in fitting and cross-validation for all
the samples).
For downstream analyses, we selected significantly modulated
proteins obtained using both univariate and multivariate
approaches: thus, we found 51 (Figure 4A) and 39 (Figure 4B)
modulated proteins in pEVs and pMSC respectively. Notably,
AAAT, CO1A1, CO1A2, COCA1, FINC, and ICAM1 were the 6
proteins modulated both in pMSCs and pEVs showing the same
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FIGURE 4 | Proteomic profile of resting and primed MSCs and corresponding EVs. (A) Differentially expressed proteins in pEVs compared to cEVs obtained both from
univariate and multivariate approach (adj p < 0.05, Fold Change (FC) > 1.5 and FC < 0.667) (n = 7). (B) Differentially expressed proteins in pMSCs compared to
cMSCs obtained both from univariate and multivariate approach (adj p < 0.05, FC > 1.5, and FC < 0.667) (n = 7). (C) Venn diagram representing modulated proteins
both in pMSCs and pEVs. (D) Immunoblot analysis of LG3BP, MOES, PTX3, and S10A6 expression in cEVs and pEVs. This blot is representative of three independent
experiments showing the same trends.
trend (Figure 4C). Interestingly, among modulated proteins in
pEVs, we found a strong down-regulation of different proteins
involved in many processes related to the immune response,
such as LG3BP (galectin-3-binding protein), PTX3 (pentraxin 3),
CCL5 (C-C motif chemokine 5), ENOA (alpha-enolase), MOES
(moesin), and S10A6 (Protein S100-A6). To confirm the results
obtained through shotgun MS, we selected 4 proteins according
to their immunomodulatory potential and we validated their
expression through western blotting. As expected, Galectin-3-
binding protein (LG3BP) and pentraxin 3 (PTX3) were up-
regulated, while moesin (MOES) and Protein S100-A6 (S10A6)
were down-regulated in pEVs compared to cEVs (Figure 4D).
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Protein Annotation and Pathway
Enrichment Analysis on Modulated
Proteins
Differentially expressed proteins of pEVs and pMSCs were
annotated on the basis of the GO terms. Considering the
pEVs dataset, we found 20 GO terms significantly enriched
in the “cellular component” category (Figure 5A), most of
which are related to exosomes and EVs, and 11 and 14 terms
enriched in “molecular function“ and “biological process”
categories, respectively (Figures S2A,C). As for the enriched
GO terms of differentially expressed proteins in pMSCs,
we found only 4 GO terms in the “cellular component”
(Figure 5B), of which the most significant was “extracellular
exosome,” only one term in “molecular function” category,
and 10 enriched terms in “biological process” category
(Figures S2B,D). As expected, many terms refer to biological
processes related to the immune system and response to
inflammatory stimuli.
To identify potentially perturbed molecular pathways, pEV-
derived modulated proteins were mapped to terms in the
KEGG database and categorized into 35 pathways significantly
enriched (adjusted p-value < 0.05) (Figures 5C,E). Notably,
the top 10 pathways included the following terms: (i) “PI3K-
AKT signaling pathway,” an important pathway involved in
cell proliferation, survival, and growth; (ii) “regulation of
actin cytoskeleton”; (iii) “focal adhesion”; and (iv) “leukocyte
trans-endothelial migration”. These pathways are crucial during
leukocyte activation, especially during leukocyte migration
through activated venular walls. Modulated proteins resulting
enriched in these four KEGG pathways are mainly down-
regulated (Figure 5G), thus suggesting a possible inhibition of
these pathways in immune effector cells, mediated by pEVs.
Pathway enrichment analysis was also performed for deregulated
proteins of pMSCs and 8 pathways resulted significantly
enriched (Figures 5D,F).
pEVs Induce a Down-Regulation of
PI3K-AKT Signaling Pathway in Activated
B Lymphocytes
To evaluate the capability of MSC-derived EVs to modulate
the PI3K-AKT signaling pathway, activated B lymphocytes were
treated with cEVs or pEVs. The expression and phosphorylation
profile of different components of PI3K-AKT signaling pathway
(PAN AKT, AKT pS473, GSK3b pS9, p70S6K, S6 pS240, S6
pS235pS236) was evaluated by flow cytometry. We observed a
strong up-regulation of the pathway during B cell activation,
especially considering the phosphorylation of the ribosomal
protein S6, one of the main PI3K-AKT downstream effectors
(Figure 6A). As expected, the treatment with pEVs induced
a significant down-modulation of the pathway compared to
cEVs (Figures 6B,C). We observed a significant reduction of S6
pS235pS236 when activated B lymphocytes were cultured with
both cEVs and pEVs. However, the treatment with pEVs led
to a significantly higher reduction compared to the treatment
with cEVs.
MSC-Derived EVs Inhibit B Cell Spreading
The second most significant KEGG pathway enriched in EV-
modulated proteins was “regulation of actin cytoskeleton.” Many
works revealed that B cells undergo dramatic morphological
reorganization following antigen-mediated activation (50–52). In
these mechanisms, the activation of actin cytoskeleton seems
to play a crucial role, especially during early events on B cell
activation (51). To test the possible role of MSC-derived EVs
to promote the reorganization of B cell actin cytoskeleton, we
evaluated the ability of B lymphocytes, either pre-treated or not
with MSC-derived EVs, to spread on coverslips coated with
immobilized F(ab′)2 anti-human IgM/IgA/IgG (53). We first
verified the specificity of F(ab′)2 anti-human IgM/IgA/IgG to
induce cell spreading (Figures 7A,B). The percentage of cell
spreading after 1 h of incubation on coated coverslip was 55%.
Spreading cells showed elongated and irregular shape with an
average area of 129 ± 59 µm2 (Figure 7B). B lymphocytes pre-
treated with pEVs showed a significantly reduced cell spreading,
with a cell area average of 111 ± 61 µm2, as compared to
the one treated with cEVs, with a cell area average of 86 ±
41 µm2 (Figure 7C). In addition, the treatment with cEVs
lowered the percentage of spreading cells to 47%, while spreading
cells were strongly reduced to 27% when B lymphocytes were
treated with pEVs (Figure 7D) We also observed differences
in terms of cell shape in the different experimental conditions.
While the morphology of spreading B cells treated with
cEVs was similar to the one of the control condition, pEVs
induced B cells to retain a spherical shape (Figure 7E).
These results confirmed the potential of MSC-derived EVs to
modulate the organization of actin cytoskeleton by inhibiting
its activation during the processes of B cell spreading. This
observation suggests another possible mechanism of action
explaining the immunomodulatory propertiesmediated byMSC-
derived EVs, in addition to the modulation of PI3K-AKT
signaling pathway.
miRNA Expression Profile of MSCs
and EVs
To determine miRNA expression pattern in MSCs and
EVs following the treatment with inflammatory stimuli, we
performed next generation miRNA sequencing. To evaluate
the overall variation of the samples, miRNA sequencing data
were analyzed by PCA (Figures 8A,B). PCA revealed a clear
separation between cMSCs and pMSCc, while cEVs and pEVs
were not clearly separated. The same trend was observed
using the hierarchical clustering analysis (HCA) among the
9 samples in terms of significantly differentially expressed
miRNAs between cMSCs and pMSCs and corresponding EVs
(Figures 8C,D). Cellular samples were completely divided into
two branches, corresponding to the treated and the control
groups, while cEVs and pEVs were not well-separated. These
observations highlight that the impact of inflammatory stimuli
on miRNA expression is much more evident in MSCs rather
than in EVs. Following the treatment with inflammatory
stimuli, we found 15 miRNAs differentially expressed in pEVs
(Figure 8E), of which 4 up- and 11 down-regulated. Some of
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FIGURE 5 | GO protein annotation and Pathway Enrichment Analysis. Cellular component GO category annotation of differentially expressed proteins in pEVs [(A), the
top 10 terms are shown] and pMSCs (B). Pathway enrichment analysis on differentially expressed proteins in pEVs [(C), the top 10 terms are shown] and pMSCs
(D). Terms with adjusted p-value < 0.05 were considered significantly enriched. Cytoscape platform based ClueGO/CluePedia pathway analysis and visualization of
differentially expressed proteins in pEVs (E) and pMSCs (F). Terms are grouped based on shared genes (kappa score) showed in different colors. The size of nodes
indicates the degree of significance. The most significant term defines the name of the group. (G) Modulation of differentially expressed proteins in pEVs enriched in
“PI3K-AKT signaling pathway,” “regulation of actin cytoskeleton,” “focal adhesion,” and “leukocyte trans-endothelial migration” KEGG pathway (FC < 0.0667 or FC >
1.5, p < 0.05).
them are known to be involved in different immunological
responses. In the cellular compartment we found 46 miRNAs
differentially expressed between cMSCs and pMSCs (Figure 8F).
Three miRNAs resulted modulated with the same trend both
in pMSCs and pEVs, i.e., miR-155-5p, miR-199a-5p, and
miR-222-3p (Figure 8G).
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FIGURE 6 | PI3K-AKT signaling pathway expression in activated B lymphocytes co-cultured with MSC-EVs. (A) Relative expression of PAN AKT, AKT pS473, GSK3b
pS9, p70S6K, S6 pS240, S6 pS235pS236 in activated B lymphocytes analyzed by flow cytometry. (B) Relative expression of PAN AKT, AKT pS473, GSK3b pS9,
p70S6K, S6 pS240, S6 pS235pS236 in activated B lymphocytes treated or not with resting or primed EVs. Wilcoxon test *p < 0.05. (C) Representative histograms
showing the levels of expression of PAN AKT, AKT pS473, GSK3b pS9, p70S6K, S6 pS240, S6 pS235pS236 in activated B lymphocytes treated or not with resting
or primed EVs.
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FIGURE 7 | B cell spreading inhibition mediated by MSC-EVs. (A) Cell area of B cells plated on coverslips coated or not with F(ab′) 2 anti-human IgM/IgA/IgG (n =
42–204). (B) Double-stained B cells with DAPI (blue) and rhodamine phalloidin (F-actin, red) before and after the induction of cell spreading (60min). (C) Cell area of B
cells pre-treated with cEVs or pEVs and then plated on coated coverslips (n = 212–398). (D) Percentage of spread B cells treated with cEVs or pEVs after 60min of
incubation on coated coverslips. (E) Double-stained B cells with DAPI (blue) and rhodamine phalloidin (F-actin, red) after 60min of incubation on coated coverslips.
The images are representative for three independent experiments with similar results (Original magnification 400x). Error bars represent mean ± SEM of three
independent experiments. t-test *p < 0.05, ***p < 0.001.
To assess the functional role of specific miRNAs in
MSC-derived EV immunomodulatory properties toward B
lymphocytes, we selected miRNAs for RT-qPCR validation by
evaluating their experimentally validated targets (Table S5)
that were mapped to the terms in the KEGG database.
Eventually, miRNA-155-5p, miRNA-199a-5p, and miRNA-
497-5p resulted the most promising miRNAs. Table S6
shows the top 20 pathways significantly enriched (adjusted
p-value < 0.05) for each miRNA. Notably, these miRNAs
can modulate the PI3K-AKT signaling pathway, one
of the pathway that we found impaired following the
treatment with MSC-derived EVs. To confirm the results
of miRNA-Sequencing, the expression of miRNA-155-5p,
miRNA-199a-5p, and miRNA-497-5p was validated through
RT-qPCR (Figure 8H).
miR-155-5p Reduce B Cell Viability and
PI3K-AKT Signaling Pathway
Due to its strong up-regulation in pEVs and its potential role
in immunomodulation processes, we investigated the effect of
miR-155-5p on B cell activity. Although the over-expression
of miR-155-5p in activated B lymphocytes did not affect
cell proliferation (data not shown), we observed a significant
reduction in cell viability (Figure 9A). Furthermore, considering
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FIGURE 8 | miRNA expression profile of MSCs and EVs following inflammatory priming. PCA plot calculated using regularized-logarithm transformation of miRNA
counts on EVs (A) and MSCs (B) samples. Heatmap summarizing differentially expressed miRNAs in pEVs (C) and pMSCs (D). Bar plot representing the log2-fold
change of differentially expressed miRNAs in pEVs (E) and pMSCs (F). (G) Venn diagram representing common differentially expressed miRNAs in pEVs and pMSCs.
(H) RT-qPCR validation of differentially expressed miRNA in pEVs (n ≥ 3). Wilcoxon test *p < 0.05.
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FIGURE 9 | Effect of miR-155-5p on B cell activity. (A) Relative cell viability of B cells transfected with double-stranded RNA mimic miR-155-5p (n = 7). (B) Relative
PI3K-AKT signaling pathway expression in B cells transfected with double-stranded RNA mimic miR-155-5p (n = 5). Wilcoxon test *p < 0.05.
that many genes belonging to PI3K-AKT signaling pathway are
targeted by miR-155-5p, we assessed its contribution on PI3K-
AKT pathway activation. As expected, miR-155-5p contributed
to reduce PAN AKT expression and ribosomal protein S6
phosphorylations (Figure 9B).
miRNA Targets Annotation and Pathway
Enrichment Analysis
As the identification of miRNA targets can provide insights
into the biological role of differentially expressed miRNA
in pEVs and pMSCs, we used miRTarBase, a resource
for experimentally validated microRNA-target interactions, to
identify the list of experimentally validated miRNA targets
(data not shown). To determine their functions, the targets
of the top 10 miRNAs modulated in pEVs and pMSCs were
annotated on the basis of the GO terms. Figures S3A,B
show the top 10 GO terms significantly enriched in the
“cellular component,” considering EVs andMSCs compartments,
respectively. Interestingly, the enrichment profile resulted almost
equal into the two compartments. A similar trend occurred
also considering “molecular function” and “biological process”
categories (Figures S3C,D,E,F). These observations suggest that
probably miRNAs modulated in pEVs only reflected the state
of miRNA expression profile of the cell of origin. Many terms
that we found in the three GO categories were related to
the transcription activity, such as “gene expression,” “RNA
binding,” “transcription factor binding,” and “transcription
coactivator activity.” Thus, we could expect that the genes
targeted by modulated miRNA in pEVs are involved in
the regulation of the transcriptional activity of target cells.
Concerning the enriched pathways, Figures S3G,H show the
top 10 KEGG pathways that could be affected by modulated
miRNA in pEVs and pMSCs, respectively. Considering pEVs,
we observed a strong enrichment of pathways related to
cancer, highlighting a potential role of MSC-derived EVs in
mediating cancer-related processes. Moreover, we found the
following terms already identified with enrichment analysis on
modulated proteins: (i) “focal adhesion,” and (ii) “regulation of
actin cytoskeleton.” Thus, the modulation of specific proteins
together with the modulation of specific miRNA in pEVs
could affect the activity of B lymphocytes, especially during
leukocyte migration.
Combination of miRNA and Proteomic
Profiles of MSCs and EVs
To verify possible correlations between miRNA and proteomic
profiles, the data frommiRNA expression profiles and proteomic
determinations were merged by using a multivariate approach.
To perform this operation, only the individuals in common with
both characterizations were retained; therefore, 4 samples were
considered. Only proteins expressed in at least 2 individuals over
4 were considered. Due to the small number of samples involved,
only PCA results are presented; however, to show only the
correlation structure of the most discriminating variables, PCA
was carried out on the first 200 variables selected by ranking-
PCA as the most discriminating for both EVs and MSCs. The
score plot of the first two PCs calculated for EVs (Figure 10A)
and MSCs (Figure 10B) allows the clear separation of the groups
of samples.
Looking at the loadings for EVs (Table S7), it is possible to
verify that Ranking-PCA first includes mainly miRNA signals
(and a lower number of proteins), while the last half of
the added signals belongs to the proteomic group. Similar
considerations can be drawn from the loadings in the case of
MSCs (Table S7); however, in this case Ranking-PCA includes
almost exclusively miRNA signals in the first 200 variables
and just a few proteins, thus indicating that in the case of
MSCs the two characterization profiles are more independent
from each other. Positive coefficients correspond to variables
(miRNAs or proteins) over-expressed in primed samples, while
variables with negative coefficients have the opposite behavior.
The loadings show a strong correlation between miRNA profiles
and proteomic signals.
miRNAs Differentially Expressed in pEVs
Modulate Pathways Affected by pEV
Proteins
To verify other correlations between miRNA and proteomic
profiles, we employed an in-silico approach to evaluate the
possible involvement of miRNAs, differentially expressed in
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FIGURE 10 | Combination of miRNA and proteomic profiles of MSCs and EVs. Score plot of the first two PCs calculated after the application of PCA to EVs (A) and
MSCs (B). Chord diagrams representing proteins belonging to “PI3K-AKT signaling pathway” (C), “regulation of actin cytoskeleton” (D), “focal adhesion” (E), and
“leukocyte trans-endothelial migration” (F) KEGG pathways targeted by miRNAs differentially expressed in pEVs.
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pEVs, in regulating some of the top enriched pathways affected
by modulated proteins. We correlated miRNA-Seq and shotgun
MS results. To this aim, we evaluated the percentage of genes
belonging to “PI3K-AKT signaling pathway,” “regulation of
actin cytoskeleton,” “focal adhesion,” and “leukocyte trans-
endothelial migration” KEGG pathways targeted by miRNAs
differentially expressed in pEVs. All 15 differentially expressed
miRNAs targeted more than 50% of genes that constitute “PI3K-
AKT signaling pathway” and “regulation of actin cytoskeleton”
pathways (61.8 and 52.8%, respectively) (Figures 10C,D).
Moreover, 14 miRNAs targeted 58 and 72.4% of genes belonging
to “leukocyte trans-endothelial migration” and “focal adhesion”
pathways, respectively (Figures 10E,F).
DISCUSSION
EV-mediated cellular communication has become a hot research
topic because of increasing evidence of EV involvement in
many physiological and pathological conditions. Depending
on their molecular composition, EVs can influence several
biological processes by directly activating cell surface receptors
and delivering molecular effectors into target cells (11–13). The
molecular composition of EVs is strictly influenced by the cell of
origin and different environmental conditions; accordingly, EVs
secreted by different cell types can modulate the immune system
depending on such molecular composition (1, 4, 18, 19).
The predominance of paracrine mechanisms in MSC-
mediated immunomodulatory effect has been broadly
demonstrated (54–57). These mechanisms include the release
of EVs responsible for the reduction of immune effector cell
activation, especially as far as B and NK cells are considered
(20). MSC priming with inflammatory cytokines dramatically
enhances their immunosuppressive properties, thus increasing
the capability of EVs they release to reduce the immune responses
(20). Furthermore, the immunoregulatory ability mediated by
MSCs was comparable to the effect mediated by corresponding
EVs, especially when primed-EVs were considered (20).
This observation strongly supports the hypothesis that MSC
immunosuppressive properties are strictly affected by the EVs
they release. Many studies have confirmed the beneficial effect
of MSC-derived EVs in vivo, paving the way for alternative
cell-free therapeutic approaches in the field of inflammatory
and autoimmune diseases (58, 59). Nevertheless, the therapeutic
application of MSC-derived EVs is still hampered by the lack
of standardized and reproducible methods of EV isolation,
characterization and quantification and by the difficulty of
large-scale production of EVs for therapeutic purposes. In
addition, considering their involvement in several physiological
and pathological processes, further pre-clinical studies are
necessary to exclude possible adverse or simply undesirable
effects of MSC-derived EVs. For this reason, a comprehensive
analysis of MSC-derived EVs allows to understand the
molecular mechanisms underlying their immunomodulatory
properties, thus identifying novel therapeutic targets as
safer and more useful alternatives to cell or EV-based
therapeutic approaches.
On the other hand, the role and prognostic significance of
EVs have been documented in a broad range of hematological
malignancies, including B-cell leukemia and lymphoma, with
a clear involvement in the development and progression
of the disease (45–47). In all these pathological conditions,
BM stromal cells represent a pivotal player in the survival,
proliferation, differentiation, and chemoresistance of neoplastic
B cells (60, 61).
Consequently, in this work we focused the analysis on
the crosstalk between MSCs and B cells, as we have recently
shown that pMSC-derived EVs strongly modulate B cell
activity. Here, we showed the effect of inflammatory stimuli
on MSC-derived EV secretion and content in terms of
miRNA and protein expression profile. We also correlated
EVs content with their immunomodulatory properties
toward B lymphocytes.
Notably, inflammatory priming induced MSCs to release
a higher percentage of exosomes compared to microvesicles,
suggesting that the role of smaller vesicles could be functionally
more crucial in mediating MSC-related immunosuppressive
mechanisms. As shown by flow cytometry, the internalization
of cEVs by B lymphocytes resulted higher than pEVs, probably
due to the different size of EVs released by MSCs in normal
or inflammatory conditions. Inflammatory stimuli affected
not only MSC-derived EV size, but also their protein and
miRNA content. Protein expression profile of MSCs and MSC-
derived EVs was deeply affected by inflammatory priming.
Interestingly, modulated proteins in cellular compartment were
mostly involved in the release of extracellular exosomes,
thus highlighting the significance of EV release by MSCs
during inflammatory processes and, consequently, their role
in MSC-mediated immunoregulation. Furthermore, modulated
proteins in pEVs are involved in different processes related
to immunological events, especially during leukocyte activation
and migration. Such processes include “PI3K-AKT signaling
pathway” and “regulation of actin cytoskeleton.” PI3K-AKT
signaling pathway is an intracellular pathway affecting the
function of several biological processes, such as cell survival, cell
cycle progression, and cellular growth (62), while the regulation
of actin cytoskeleton is pivotal during leukocyte activation,
especially during the early stage of B cell receptor activation
(50). The proteins belonging to these pathways resulted
down-modulated, thus suggesting their possible involvement
during the process of immunosuppression toward effector
cells. As expected, pEVs induced a strong down-modulation
of PI3K-AKT components and a substantial impairment of
actin reorganization in B lymphocytes during the early stages
of activation. These results suggest some of the potential
mechanisms of action underlying the immunomodulatory
properties mediated by MSC-derived EVs. Pathway enrichment
analysis for modulated proteins in pMSCs revealed only four
terms, including “antigen processing and presentation” pathway
as significantly enriched, highlighting the well-known capacity
of MSCs to present antigen via major histocompatibility
complex (MHC) molecules, which are constitutively expressed
and up-regulated on MSCs following inflammatory priming
(20, 63). Similarly, only the term “identical protein binding”
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resulted significantly enriched in the molecular function GO
category. Taken together, our results showed that inflammatory
stimuli mainly affect the protein content of EVs compared
to the originating cells, confirming their crucial role and
the predominance of paracrine mechanisms in mediating
immunomodulatory functions. Focusing on modulated protein
in pEVs, we found several proteins involved in many processes
related to immune response, such as LG3BP, PTX3, MOES,
and S10A6. Galectins are a family of beta-galactoside-binding
proteins implicated in modulating cell-cell and cell-matrix
interactions. LG3BP promotes integrin-mediated cell adhesion
and influences different processes of immune response, such
as NK cell activation and lymphokine-activated killer (LAK)
cell cytotoxicity (64). PTX3 is involved in the regulation of
innate resistance to pathogens and inflammatory reactions. The
expression of this protein is induced by inflammatory cytokines
in several mesenchymal and epithelial cell types (65). MOES
and S10A6 are also involved in immune response mechanisms,
especially regarding the organization of actin cytoskeleton and
cell motility (66–68). Furthermore, the Ezrin, Radixin, and
Moesin (ERM) protein family is not only involved in the
cytoskeletal reorganization; such proteins are also involved in
the transmission of signals in response to different extracellular
stimuli through their ability to crosslink transmembrane
receptors with downstream signaling components in B cells (68).
Considering their function, each of such modulated protein
could contribute to immunoregulatory activity mediated by
MSC-derived EVs. In addition, pEVs showed a strong up-
regulation of ITI components. ITI represents a family of
structurally related plasma serine protease inhibitors involved
in extracellular matrix stabilization (69). Frequent loss of
expression of ITIH genes is recurring in multiple human
solid tumors, thus promoting tumor metastasis (70). This
observation further strengthens the role of MSC-derived EVs
in cancer, with a potential therapeutic action in preventing
tumor metastasis.
Inflammatory microenvironment affected not only MSC-
derived EVs proteins, but also miRNA expression. In
consideration of miRNA stability and involvement inmodulating
gene expression, their role in cell-to-cell communication
mediated by EVs has been increasingly studied in the last
years. As for miRNA overall variation following inflammatory
priming, enriched GO terms resulted similar in pMSCs and
pEVs, showing less remarkable differences between cellular
and EV compartment in miRNA composition as compared
to proteins composition. Modulated miRNAs influence many
processes related to transcription activity; accordingly, pathway
enrichment analysis showed a strong enrichment of pathways
related to cancer in both dataset. On the other hand, there is a
clear evidence that MSCs and MSC-derived EVs can enhance
or suppress tumor progression depending on tumor model and
stage considered (71–73). Nevertheless, differentially expressed
miRNAs in pEVs are also involved in immunomodulatory
processes. Among these, we identified “focal adhesion” and
“regulation of actin cytoskeleton” KEGG pathways, already
found amongst modulated proteins. Thus, the modulation
of specific proteins together with the modulation of specific
miRNAs in pEVs could affect the activity of immune effector
cells, especially during leukocyte migration.
Protein and miRNA molecules contained in MSC-derived
EVs following inflammatory priming are strictly connected.
They could be transferred into target cells and contribute
synergistically to the regulation of immune effector cell activity.
Notably, we found that all differentially expressed miRNAs in
pEVs influence the most significant enriched pathways resulting
from the protein differential expression analysis. Furthermore,
many of them have a crucial role in immunological processes
in different cellular contexts (74). In particular, miRNA-155-
5p is one of the most well-characterized miRNA regulating
immune response (75–77). Here, we showed that miRNA-155-
5p has a direct capability to reduce cell viability in activated B
lymphocytes. This effect could be in part mediated by its ability
to act as negative regulator of PI3K/AKT signaling pathway, one
of the pathways we proved to be impaired following the treatment
with MSC-derived EVs.
In summary, our data show that MSC-derived EVs
contain several molecules potentially responsible for their
immunomodulatory properties and potentially involved in
MSC/B-cell crosstalk; in particular, specific molecules modulated
in pEVs are capable of influencing typical immune effector cell
activity, thus representing novel potential therapeutic targets that
could be further investigated in the field of inflammatory and
autoimmune diseases as well as in neoplastic microenvironment
of B-cell malignancies.
MATERIALS AND METHODS
Cell Culture
MSCs were isolated from BM aspirates of healthy donors
(informed consent, approved by Ethical Committee of Azienda
Ospedaliera Universitaria Integrata Verona; N. 1828, May 12,
2010 “Institution of cell and tissue collection for biomedical
research in Onco-Hematology”) and characterized as already
described (78, 79). MSCs were cultured in DMEM supplemented
with 10% heat-inactivated fetal bovine serum (FBS), 1%
penicillin-streptomycin, and 2% L-Glutamine (all from Sigma-
Aldrich). All experiments were performed between passages 2
and 7. MSCs at 80% confluence were treated or not for 48 h
with 10 ng/mL IFN-γ and 15 ng/mL TNF-α (R&D Systems)
to induce inflammatory priming. PBMCs were isolated from
human blood using Lymphoprep (Stemcells Technologies). B
lymphocytes were isolated from PBMCs using immunomagnetic
negative selection (Miltenyi Biotec) with at least 95% cell purity,
as evaluated by flow cytometry (78, 79). B lymphocytes were
cultured in RPMI medium supplemented with 10% FBS, 1%
penicillin-streptomycin and 2% L-Glutamine (all from Sigma-
Aldrich). B lymphocytes were activated with 5µg/mL anti-
human IgM+IgA+IgG (F(ab′)2, Jackson Immunoresearch), 50
IU/mL rhIL-2 (Novartis), 50 ng/mL polyhistidine-tagged CD40
ligand, 5µg/mL anti-polyhistidine antibody (R&D Systems),
and 0.5µg/mL CpG ODNs (Invitrogen). The proliferation was
assessed by flow cytometry on viable TOPRO-3neg CD45pos cells
by using FlowJo software (TreeStar) as the percentage of cells
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undergoing at least one cell division. B cells and MSC were
co-cultured in allogeneic setting.
Purification, Characterization and
Quantification of MSC-Derived EVs
EVs were isolated from conditioned medium by
ultracentrifugation as already described. EVs quantification
was performed through BCA Protein Assay (Thermo Fisher
Scientific). Particle size was evaluated by dynamic light scattering
(DLS) measurements using a Zetasizer Nano ZS (Malvern
Instruments, 4mV He-Ne laser, λ0 = 633 nm, θ = 173◦).
To assess the surface marker profile, 10 µg of EVs were
analyzed using MACSPlex Exosome Kit (Miltenyi Biotec),
a multiplex bead-based platform that allows the detection
of 37 surface epitopes. Samples were analyzed with a FACS
Canto II (BD Bioscences). Mean fluorescence values were
background corrected according to the protocol. In vitro
experiments with MSC-EVs were carried out using pooled EVs
derived from at least 5 MSC donors, with the aim to reduce
interindividual variability.
EV Internalization and Fluorescence
Microscopy
To assess EV internalization by B lymphocytes, MSC membranes
and RNA were stained with 200µM Vybrant Dil Cell-
labeling Solution and 500 nM Syto RNA Select (both from
Life Technologies), respectively. Then, labeled or unlabeled
MSCs were co-cultured in presence of B lymphocytes (1:1)
and EV internalization was assessed after 24, 48, and 72 h. At
the end of the co-culture, cells were stained with anti-CD45-
PerCP-Vio770 (Miltenyi Biotec) and TOPRO-3 Iodide (Life
Technologies), allowing us to exclude MSCs from our analyses
performed on CD45 positive viable cells by flow cytometry.
Furthermore, EVs were directly stained with 10µM Vybrant
Dil Cell-labeling Solution and 10µM Syto RNA Select and
washed with Exosome Spin Column (MW 3000) (Thermo Fisher
Scientific). Then, activated B lymphocytes were cultured for
24 h with of labeled or unlabeled EVs (30 µg/2 × 104 B
cells). EVs internalization were evaluated by flow cytometry
using the same gating strategy used for MSC/B cell co-
cultures. For fluorescence microscopy experiments, B cells were
loaded into the CytoSpin centrifuge’s sample chamber and
centrifuged 300xg for 5min. Finally, cells were stained with
1µg/mL Hoechst (Thermo Fisher) in PBS and then analyzed
by fluorescence microscopy using a Zeiss Axio Observer Z1
microscope (Carl Zeiss).
Sample Preparation for Shotgun
Proteomics
EVs were collected and lysed in PBS supplemented with protease
inhibitors (Roche) and 1% Sodium Dodecyl Sulfate (SDS)
(Bio-Rad). Protein extraction was performed by 5–6 cycles
of sonication. Then, ice-cold acetone was added to samples
and protein precipitation was conducted overnight at −20◦C.
Samples were then centrifuged at 14,000xg for 10min at 4◦C,
and pellet was resuspended in 100mM NH4HCO3. Protein
concentration was measured with BCA Protein Assay. Samples
were subjected to denaturation with trifluoroethanol, reduced
with DTT 200mM, alkylation with Iodoacetamide 200mM, and
digested with Trypsin/Lys-C (Promega). The peptide digests
were desalted on the Discovery R© DSC-18 solid phase extraction
(SPE) 96-well Plate. The SPE plate was preconditioned with
1ml of acetonitrile and 2ml of water. After the sample
loading, the SPE was washed with 1ml of water. The adsorbed
proteins were eluted with 800 µl of acetonitrile:water (80:20).
After the desalting, the sample was vacuum-evaporated and
reconstituted with 20 µl of 0.05% formic acid in water before
LC-MS/MS analysis.
Shotgun Mass Spectrometry
The digested proteins were analyzed with a micro-LC Eksigent
Technologies (Eksigent) system interfaced with a 5600+
TripleTOF system (AB Sciex) equipped with DuoSpray
Ion Source and Calibrant Delivery System. More detailed
information on instrument setting and label-free quantification
is available in Supplementary Materials and Methods.
Two DDA and three DIA acquisitions were
performed (80).
The DDA files were searched using Protein Pilot software
v. 4.2 and Mascot v. 2.4. Trypsin/Lys-C as digestion enzyme
was specified for both the software. For Mascot we used 2
missed cleavages, the instrument was set to ESI-QUAD-TOF
and the following modifications were specified for the search:
carbamidomethyl cysteines as fixed modification and oxidized
methionine as variable modification. A search tolerance of 50
ppm was specified for the peptide mass tolerance, and 0.1 Da
for the MS/MS tolerance. The charges of the peptides to search
for were set to 2 +, 3 +, and 4 +, and the search was set on
monoisotopic mass (81, 82).
The UniProt Swiss-Prot reviewed database containing human
proteins (version 2015.07.07, containing 42131 sequence entries)
was used and a target-decoy database search was performed. False
Discovery Rate was fixed at 1%.
The protein quantification was performed by integrating the
extracted ion chromatogram of all the unique ions for a given
peptide and was carried out with PeakView 2.0 and MarkerView
1.2. Six peptides per protein and six transitions per peptide were
extracted from the SWATH files. Shared peptides were excluded
as well as peptides with modifications. Peptides with FDR lower
than 1.0% were exported in MarkerView for the t-test (83).
Proteomic t-test statistical analysis was performed with
MarkerView. Proteins were considered modulated in presence of
a fold change≥ 1.50 or ≤ 0.5 and a p-value< 0.05.
Western Blot Analysis
Immunoblot analysis on EV candidate proteins was performed
as previously described (84). Briefly, protein samples from
different biological replicates were diluted 1:1 with Laemmli’s
sample buffer (62.5mM Tris-HCl, pH 6.8, 25% glycerol, 2%
SDS, 0.01% Bromophenol Blue), heated for 5min at 90◦C, and
separated by SDS/polyacrylamide gel electrophoresis (PAGE)
on 4–20% T acrylamide gels in Tris/glycine/SDS buffer.
After separation on SDS-PAGE, proteins were electroblotted
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on PVDF membrane and subjected to immunodetection.
Amido Black staining (Sigma-Aldrich) was used to confirm
equal protein loading in different lanes. Membranes were
incubated with the different primary antibodies diluted in 1%
non-fat dried milk, 0.05% Tween-20 in Tris-buffered saline
for 3 h at room temperature. Blots were then incubated
1 h at room temperature with the appropriate horseradish
peroxidase (HRP)-conjugated secondary antibody (seeTable S8).
Immunocomplexes were visualized by chemiluminescence using
the Chemidoc MP imaging system (Bio-Rad) and the intensity
of the chemiluminescence signal was measured by processing the
image with Image Lab software (Bio-Rad).
Univariate and Multivariate
Statistical Analysis
Proteomic data were analyzed by univariate and multivariate
statistical analyses. The univariate approach consisted in
selecting proteins modulated at least in 4 samples among 7
processed samples using a cut off with adjusted p-values of <
0.05 and fold change of >1.5 or <0.0667. Principal Component
Analysis (PCA) was applied to provide a general overview of the
correlations existing between the variables and the existence of
sample groups (see Supplementary Materials and Methods).
PCA is exploited in Ranking-PCA to select the most
discriminating variables (i.e., candidate biomarkers) between two
groups of samples and sort them according to their decreasing
discrimination ability (85–88).
PLS is a multivariate regression method establishing a
relationship between one or more dependent variables (Y) and
a group of descriptors (X). X and Y variables are modeled
simultaneously, to find the latent variables (LVs) in X that
will predict the LVs in Y. PLS can be applied for classification
purposes by establishing an appropriate Y related to the
association of each sample to a class. Since two classes are
present in this case (control and primed samples), a binary Y
variable is added to each dataset, coded so that−1 is attributed
to control samples and +1 to primed samples. The regression
is then carried out between X-block variables (protein counts)
and the Y just established. This application for classification
purposes is called PLS-DA (89). Here, Ranking-PCA was
used as selection method to provide the list of all candidate
biomarkers in decreasing order of discriminant ability of the
final model. The list identified in this way was then used for
classification, based on PLS-DA (89), to provide a final model
able to discriminate the two classes of samples present. The
analysis was done considering 1 PC in Ranking-PCA and 1
LV in the final PLS-DA models (for MSCs, only the first 200
proteins selected by Ranking-PCA were included in the PLS-
DA model). Both the selection of the significant proteins by
Ranking-PCA and the calculation of the performance ability
of the PLS-DA models were obtained by leave-one-out (LOO)
cross-validation: all the replications of the same sample (both
control and primed replications) were eliminated in turn from
the calculation and used to provide an evaluation of the final
predictive ability. Since 7 individuals were available, only LOO
was applied, and one individual was eliminated at a time. In
Ranking-PCA just one PC was used for calculation, due to the
small number of degrees of freedom available. The classification
performances were evaluated by calculating model accuracy, i.e.,
the ratio of correctly assigned samples, and the Non-Error-Rate%
(NER%), i.e., the average of the accuracies calculated for each
class independently.
RNA Extraction and Quality Controls
Total RNA was extracted using miRNeasy Mini Kit
(Qiagen) and miRNA enriched fraction was obtained
using mirPremier microRNA Isolation Kit (Sigma Aldrich)
according to manufacturer’s instructions. RNA was quantified
with the Qubit RNA Assay kit (Life Technologies). RNA
purity and integrity were assessed at the Nanodrop 1000
spectrophotometer (Thermo Fisher Scientific) and by
capillary electrophoresis on an Agilent Bioanalyzer (Agilent
Technologies), respectively.
Small RNA Sequencing
Small RNA libraries were prepared using theNebNext Small RNA
Library Preparation Kit (New England Biolabs) for miRNA and
short non-coding RNAs sequencing according to manufacturer’s
instructions, starting from 200 ng RNA and using 15 PCR
cycles. Each library was analyzed with the High Sensitivity
DNA chip (Agilent) using Agilent 2100 Bioanalyzer. Pools of
12 libraries were concentrated with AMPure XP magnetic beads
(Beckman Coulter) and eluted in 40 µl of nuclease free water.
The eluate from each pool was loaded onto a 6% precast gel (Life
Technologies), a ≈146 bp band was cutted, purified with a 5 µl
filter with Qiaquick gel extraction kit (Qiagen) and quantified
using the Qubit DNA HS (Life Technologies). The miRNAseq
libraries were sequenced on a NextSeq500 sequencer (Illumina)
using 75 bp-reads and producing on average 2,047,034,738 reads
per sample.
Identification of Differentially
Expressed miRNAs
Illumina sequencing was used to generate small RNA reads from
9 biological replicates of primed and control EVs/MSCs. Raw
fastq files were analyzed to evaluate their quality using FastQC
software (http://www.bioinformatics.babraham.ac.uk/projects/
fastqc). Adapter trimming was performed using TrimGalore
(https://www.bioinformatics.babraham.ac.uk/projects/trim_
galore) specifying length and max-length parameters. After this
step, only reads with length between 16 and 26 nucleotides
remained for further analysis. Clipped reads were aligned using
Bowtie2 to the GRCh38 human genome built from ENSEMBL,
using the preset of parameters –very-sensitive-local to obtain
high-score matches (90). The summarization of the reads was
performed using featureCounts (91), using the GFF annotation
file provided by miRBase. Differential expression analysis
was conducted through the R/Bioconductor package DESeq2
comparing primed vs. control EV/MSC samples, using a 5% FDR
cut-off (92).
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Real-Time qPCR
For miRNA analysis, 10 ng of RNA was retro-transcribed
with TaqMan MicroRNA Reverse Transcription Kit (Applied
Biosystems). Relative miRNA expression was determined using
TaqMan Universal Master Mix II, no UNG and Taqman
microRNA assay (Applied Biosystems) and normalized to
U6. All reactions were performed in triplicates and run on
LightCycler 480 Instrument II (Roche) following manufacturer’s
instructions. Data obtained from the qPCR were analyzed using
the11Ct method.
GO Annotation and Pathway Enrichment
Analysis of Differentially
Expressed Proteins
GO annotation of significantly altered proteins expressed in
pEVs was performed with DAVID v6.8 Functional Annotation
Bioinformatics Tools (https//david.ncifcrf.gov/). The enrichment
analysis for GO cellular component, biological process and
molecular function was done by comparing the GO terms of
identified proteins against the human proteome. This analysis
detected the significant (p adj< 0.05) over-representation of GO
terms in the submitted dataset. In addition, ClueGO v2.3.3, was
used for analyzing significantly enriched KEGG pathways (p adj
< 0.05) with the human genome as background (93). The nodes
in functionally grouped networks were linked based on their
kappa score level (0.4) in ClueGO; the GO Tree Levels ranged
from levels 3–8.
GO Annotation and Pathway Enrichment
Analysis of Modulated miRNAs and
miRNA Targets
Functional enrichment of top 10 (based on adjusted p-value)
differentially expressed miRNAs in pEVs and pMSCs was
performed using DIANA-miRPath v3.0 (94). The enrichment
analysis was conducted on KEGG and GO using only
experimentally validated miRNA-target interactions provided by
DIANA-TarBase v7.0, with genes union as merging algorithm.
Furthermore, the parameter conservative stats were used to have
a more stringent statistical test. Only terms with an adjusted
p-value< 0.01 were selected.
In vitro Cell Spreading
Glass coverslips were coated at room temperature for 2 h with
5µg/mL of F(ab′)2. 15x104 B lymphocytes, pre-treated for 24 h
with resting, and primed EVs, were left to spread at 37◦C
on coverslips for different time points. Then, cells were fixed
with 4% paraformaldehyde in PBS (ChemCruz), permeabilized
with 0.5% Triton X-100 (AppliChem) and stained with DAPI
and rhodamine phalloidin (both from Life Technologies). Cell
spreading was quantified by measuring the mean cell area (µm2)
by using AxioVision 4.8.2 software (Carl Zeiss).
miRNA Mimic Transient Transfection
Activated B cells were seeded at 2 × 105/200 µL per well.
After 24 h, cells were transfected with 10 nM of miR-155-5p
mimic (5′UUAAUGCUAAUCGUGAU AGGGGU) or negative
control miRNA (5′GAUGGCAUU CGAUCAGUUCUA) both
from Exiqon using INTERFERin (Polyplus-transfection S.A.).
After 6 h, complete RPMI medium supplemented with stimuli
was added to each well. Finally, cells were harvested for the
functional analyses after 24, 96, or 120 h.
PI3K/AKT Signaling Pathway
Expression Profile
B lymphocytes were cultured for 4 days in presence or absence of
EVs (30 µg EVs/2x104 cells) or transfected with miRNAMimics.
At the end of culture, cells were harvested and stained with
CD45-PerCpVio700 and Viobility 405/520 Fixable Dye (both
from Miltenyi Biotec). Then, cells were fixed and permeabilized
using Cell Signaling Buffer Set A (Miltenyi Biotec) and stained
with Anti-AKT pS473-Vio515, Anti-AKT Pan (PKB)-APC, Anti-
GSK3B pS9-PE, Anti-p70 S6 Kinase-FITC, Anti-S6 pS235/pS236-
PE, and Anti-S6 pS240-APC (all from Miltenyi Biotec)
according to manufacturer’s instructions. Protein expression
was assessed by flow cytometry. Data analysis was performed
using FlowJo software (TreeStar). Data were expressed as mean
± SEM. Statistical analysis was performed by Pism software
(GraphPad) using the Wilcoxon test. P < 0.05 was considered
statistically significant.
Cell Proliferation and Viability Assay
To evaluate the effect of selected miRNAs on B cell proliferation,
cells were activated and stained with 5µM carboxyfluorescein
succinimidyl ester (CFSE, Life Technologies). After 24 h, cells
were transfected with miRNA mimics and negative control.
After 4 days, cells were harvested and stained with anti-human
CD45-PerCP-Vio700 (Milteniy Biotec) and TOPRO-3 Iodide
(Life Technologies). The effect of selectedmiRNA on cell viability
was assessed by flow cytometry using AnnexinV/7AAD staining.
Following 24 h stimulation, cells were transfected with miRNA
mimics and negative control. After 24 h, cells were harvested and
stained with anti-human CD45-APC (Milteniy Biotec), Annexin
V-FITC (Milteniy Biotec) and 7AAD (BD Biosciences). Cell
viability was evaluated on CD45posAnnexin Vneg 7AADneg cells
using FlowJo software (TreeStar). Data were expressed as mean
± SEM. Statistical analysis was performed by Prism software
(GraphPad) using the Wilcoxon test. P< 0.05 was considered
statistically significant.
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